Colon Cancer
Oncology Drug Development Update - EGFr-Targeted Drugs: Vectibix Setback, EGFr Testing
Published in Cancer Weekly, April 17th, 2007
Amgen's recent discontinuation of treatment with Vectibix (panitumumab), the first fully human IgG2 monoclonal antibody (MAb) targeting the epidermal growth factor receptor (EGFr), in the phase IIIb Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial is a disappointing setback. PACCE was evaluating the addition of Vectibix to a regimen of standard oxaliplatin- or irinotecan-based chemotherapy and bevacizumab (Avastin; Genentech), an antiangiogenic vascular endothelial growth factor (VEGF) inhibitor, for first line treatment of metastatic colorectal cancer (CRC). The trial was halted after preliminary review of data from a pre-planned interim efficacy analysis, scheduled after...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-04-17)
More Articles from Cancer Weekly
- Cancer Vaccines
Bavarian Nordic A/S presents annual results 2006 - Cancer Vaccines
GlaxoSmithKline Submits Biologics License Application to U.S. Food and Drug Administration for CERVARIX - Immunotherapy
Inovio Biomedical's DNA Delivery Technology for Immunotherapy to Be Presented at Drug Delivery Conference - Cancer Gene Therapy
Data on cancer gene therapy discussed by researchers at University of Colorado, Denver and Health Sciences Center - Cancer Gene Therapy
Investigators at University of Texas, M. D. Anderson Cancer Center target cancer gene therapy - Cancer Gene Therapy
National Cancer Center Research Institute reports research in cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
